Which has higher valuation and earnings, AEHR or TRNS?

Transcat has higher revenue and earnings than Aehr Test Systems. Aehr Test Systems is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aehr Test Systems $58.97M 49.77 -$3.91M -$0.38 N/A Transcat $331.88M 2.48 $5.38M $0.58 151.79

Does the media favor AEHR or TRNS?

In the previous week, Aehr Test Systems had 1 more articles in the media than Transcat. MarketBeat recorded 3 mentions for Aehr Test Systems and 2 mentions for Transcat. Transcat's average media sentiment score of 1.08 beat Aehr Test Systems' score of 0.82 indicating that Transcat is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aehr Test Systems 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Transcat 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, TRNS or ALNT?

Allient has higher revenue and earnings than Transcat. Allient is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Transcat $331.88M 2.48 $5.38M $0.58 151.79 Allient $554.48M 2.63 $22.03M $1.43 59.97

Is TRNS or ALNT more profitable?

Allient has a net margin of 4.25% compared to Transcat's net margin of 1.62%. Allient's return on equity of 12.47% beat Transcat's return on equity. Company Net Margins Return on Equity Return on Assets Transcat 1.62% 5.84% 3.78% Allient 4.25% 12.47% 6.37%

Does the media refer more to TRNS or ALNT?

In the previous week, Allient had 2 more articles in the media than Transcat. MarketBeat recorded 4 mentions for Allient and 2 mentions for Transcat. Transcat's average media sentiment score of 1.08 beat Allient's score of 0.47 indicating that Transcat is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Transcat 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allient 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, TRNS or ALMR?

Transcat has higher revenue and earnings than Alamar Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Transcat $331.88M 2.48 $5.38M $0.58 151.79 Alamar Biosciences $87.16M 17.11 N/A N/A N/A

Does the media favor TRNS or ALMR?

In the previous week, Transcat and Transcat both had 2 articles in the media. Transcat's average media sentiment score of 1.08 beat Alamar Biosciences' score of 0.93 indicating that Transcat is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Transcat 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TRNS or EYPT?

In the previous week, Transcat and Transcat both had 2 articles in the media. Transcat's average media sentiment score of 1.08 beat Eyepoint Pharmaceuticals' score of 0.93 indicating that Transcat is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Transcat 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Transcat (TRNS) Competitors

$88.04 -1.96 (-2.18%)

Closing price 04:00 PM Eastern

Extended Trading

$88.07 +0.03 (+0.03%)

As of 04:04 PM Eastern

Compare

TRNS vs. AEHR, ALNT, ALMR, EYPT, and FEIM

Should you buy Transcat stock or one of its competitors? MarketBeat compares Transcat with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Transcat include Aehr Test Systems (AEHR), Allient (ALNT), Alamar Biosciences (ALMR), Eyepoint Pharmaceuticals (EYPT), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry.

How does Transcat compare to Aehr Test Systems?

Aehr Test Systems (NASDAQ:AEHR) and Transcat (NASDAQ:TRNS) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

69.7% of Aehr Test Systems shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 6.8% of Aehr Test Systems shares are owned by company insiders. Comparatively, 2.8% of Transcat shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Aehr Test Systems had 1 more articles in the media than Transcat. MarketBeat recorded 3 mentions for Aehr Test Systems and 2 mentions for Transcat. Transcat's average media sentiment score of 1.08 beat Aehr Test Systems' score of 0.82 indicating that Transcat is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aehr Test Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aehr Test Systems has a beta of 3.17, indicating that its share price is 217% more volatile than the broader market. Comparatively, Transcat has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

Transcat has a net margin of 1.62% compared to Aehr Test Systems' net margin of -25.23%. Transcat's return on equity of 5.84% beat Aehr Test Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aehr Test Systems	-25.23%	-7.15%	-6.15%
Transcat	1.62%	5.84%	3.78%

Transcat has higher revenue and earnings than Aehr Test Systems. Aehr Test Systems is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aehr Test Systems	$58.97M	49.77	-$3.91M	-$0.38	N/A
Transcat	$331.88M	2.48	$5.38M	$0.58	151.79

Aehr Test Systems currently has a consensus price target of $68.00, indicating a potential downside of 27.13%. Transcat has a consensus price target of $105.33, indicating a potential upside of 19.64%. Given Transcat's stronger consensus rating and higher possible upside, analysts clearly believe Transcat is more favorable than Aehr Test Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aehr Test Systems	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Transcat beats Aehr Test Systems on 12 of the 17 factors compared between the two stocks.

How does Transcat compare to Allient?

Transcat (NASDAQ:TRNS) and Allient (NASDAQ:ALNT) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Allient had 2 more articles in the media than Transcat. MarketBeat recorded 4 mentions for Allient and 2 mentions for Transcat. Transcat's average media sentiment score of 1.08 beat Allient's score of 0.47 indicating that Transcat is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allient	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Transcat has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Allient has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

98.3% of Transcat shares are held by institutional investors. Comparatively, 61.6% of Allient shares are held by institutional investors. 2.8% of Transcat shares are held by insiders. Comparatively, 15.0% of Allient shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Allient has higher revenue and earnings than Transcat. Allient is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.48	$5.38M	$0.58	151.79
Allient	$554.48M	2.63	$22.03M	$1.43	59.97

Allient has a net margin of 4.25% compared to Transcat's net margin of 1.62%. Allient's return on equity of 12.47% beat Transcat's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Allient	4.25%	12.47%	6.37%

Transcat currently has a consensus target price of $105.33, suggesting a potential upside of 19.64%. Allient has a consensus target price of $77.33, suggesting a potential downside of 9.83%. Given Transcat's higher probable upside, equities research analysts clearly believe Transcat is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Allient	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Allient beats Transcat on 12 of the 17 factors compared between the two stocks.

How does Transcat compare to Alamar Biosciences?

Transcat (NASDAQ:TRNS) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

98.3% of Transcat shares are held by institutional investors. 2.8% of Transcat shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Transcat and Transcat both had 2 articles in the media. Transcat's average media sentiment score of 1.08 beat Alamar Biosciences' score of 0.93 indicating that Transcat is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Transcat has higher revenue and earnings than Alamar Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.48	$5.38M	$0.58	151.79
Alamar Biosciences	$87.16M	17.11	N/A	N/A	N/A

Transcat currently has a consensus target price of $105.33, suggesting a potential upside of 19.64%. Alamar Biosciences has a consensus target price of $30.00, suggesting a potential upside of 39.47%. Given Alamar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Alamar Biosciences is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Transcat has a net margin of 1.62% compared to Alamar Biosciences' net margin of 0.00%. Transcat's return on equity of 5.84% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Alamar Biosciences	N/A	N/A	N/A

Summary

Transcat beats Alamar Biosciences on 8 of the 12 factors compared between the two stocks.

How does Transcat compare to Eyepoint Pharmaceuticals?

Transcat (NASDAQ:TRNS) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Transcat presently has a consensus price target of $105.33, indicating a potential upside of 19.64%. Eyepoint Pharmaceuticals has a consensus price target of $31.80, indicating a potential upside of 157.91%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

98.3% of Transcat shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 2.8% of Transcat shares are owned by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Transcat has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

Transcat has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.48	$5.38M	$0.58	151.79
Eyepoint Pharmaceuticals	$31.37M	32.95	-$231.96M	-$3.50	N/A

Transcat has a net margin of 1.62% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Transcat's return on equity of 5.84% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

In the previous week, Transcat and Transcat both had 2 articles in the media. Transcat's average media sentiment score of 1.08 beat Eyepoint Pharmaceuticals' score of 0.93 indicating that Transcat is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Transcat and Eyepoint Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Transcat compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and Transcat (NASDAQ:TRNS) are both small-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

58.6% of Frequency Electronics shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 28.0% of Frequency Electronics shares are held by company insiders. Comparatively, 2.8% of Transcat shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Frequency Electronics has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Transcat has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Frequency Electronics has a net margin of 10.78% compared to Transcat's net margin of 1.62%. Frequency Electronics' return on equity of 12.69% beat Transcat's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	10.78%	12.69%	7.84%
Transcat	1.62%	5.84%	3.78%

In the previous week, Transcat had 1 more articles in the media than Frequency Electronics. MarketBeat recorded 2 mentions for Transcat and 1 mentions for Frequency Electronics. Transcat's average media sentiment score of 1.08 beat Frequency Electronics' score of 0.93 indicating that Transcat is being referred to more favorably in the news media.

Company	Overall Sentiment
Frequency Electronics	Positive
Transcat	Positive

Frequency Electronics has higher earnings, but lower revenue than Transcat. Frequency Electronics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$69.81M	9.39	$23.69M	$0.75	88.84
Transcat	$331.88M	2.48	$5.38M	$0.58	151.79

Frequency Electronics currently has a consensus price target of $43.67, indicating a potential downside of 34.46%. Transcat has a consensus price target of $105.33, indicating a potential upside of 19.64%. Given Transcat's higher possible upside, analysts plainly believe Transcat is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Frequency Electronics and Transcat tied by winning 8 of the 16 factors compared between the two stocks.

Get Transcat News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRNS vs. The Competition

Export

Metric	Transcat	INSTRU Industry	Computer Sector	NASDAQ Exchange
Market Cap	$840.66M	$3.16B	$38.79B	$11.95B
Dividend Yield	N/A	1.00%	3.15%	5.61%
P/E Ratio	151.80	73.94	163.24	21.87
Price / Sales	2.48	3.67	629.28	105.21
Price / Cash	19.28	26.92	47.72	54.72
Price / Book	2.73	4.13	9.46	6.70
Net Income	$5.38M	$73.46M	$1.07B	$337.26M
7 Day Performance	-2.39%	-2.82%	-3.27%	-1.41%
1 Month Performance	15.46%	4.86%	2.87%	1.15%
1 Year Performance	17.54%	73.71%	153.02%	22.61%

Transcat Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRNS Transcat	3.4882 of 5 stars	$88.04 -2.2%	$105.33 +19.6%	+17.4%	$840.66M	$331.88M	151.80	1,413	Positive News
AEHR Aehr Test Systems	1.902 of 5 stars	$101.33 +6.0%	$68.00 -32.9%	+700.6%	$3.18B	$58.97M	N/A	90	Gap Up
ALNT Allient	2.7662 of 5 stars	$88.74 +1.8%	$77.33 -12.9%	+160.6%	$1.50B	$560.59M	61.60	2,478
ALMR Alamar Biosciences	4.5167 of 5 stars	$19.21 flat	$30.00 +56.2%	N/A	$1.33B	$87.16M	N/A	222
EYPT Eyepoint Pharmaceuticals	2.9241 of 5 stars	$11.62 +1.5%	$31.80 +173.6%	+31.8%	$983.46M	$7.61M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRNS) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Transcat (TRNS) Competitors

TRNS vs. AEHR, ALNT, ALMR, EYPT, and FEIM

How does Transcat compare to Aehr Test Systems?

Summary

How does Transcat compare to Allient?

Summary

How does Transcat compare to Alamar Biosciences?

Summary

How does Transcat compare to Eyepoint Pharmaceuticals?

Summary

How does Transcat compare to Frequency Electronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRNS vs. The Competition

Transcat Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Transcat (TRNS) Competitors

TRNS vs. AEHR, ALNT, ALMR, EYPT, and FEIM

How does Transcat compare to Aehr Test Systems?

Do institutionals and insiders believe in AEHR or TRNS?

Does the media favor AEHR or TRNS?

Which has more risk and volatility, AEHR or TRNS?

Is AEHR or TRNS more profitable?

Which has higher valuation and earnings, AEHR or TRNS?

Do analysts prefer AEHR or TRNS?

Summary

How does Transcat compare to Allient?

Does the media refer more to TRNS or ALNT?

Which has more risk & volatility, TRNS or ALNT?

Do insiders & institutionals hold more shares of TRNS or ALNT?

Which has preferable valuation and earnings, TRNS or ALNT?

Is TRNS or ALNT more profitable?

Do analysts rate TRNS or ALNT?

Summary

How does Transcat compare to Alamar Biosciences?

Do institutionals and insiders have more ownership in TRNS or ALMR?

Does the media favor TRNS or ALMR?

Which has better valuation and earnings, TRNS or ALMR?

Do analysts rate TRNS or ALMR?

Is TRNS or ALMR more profitable?

Summary

How does Transcat compare to Eyepoint Pharmaceuticals?

Do analysts prefer TRNS or EYPT?

Do institutionals and insiders believe in TRNS or EYPT?

Which has more risk & volatility, TRNS or EYPT?

Which has preferable earnings and valuation, TRNS or EYPT?

Is TRNS or EYPT more profitable?

Does the media prefer TRNS or EYPT?

Summary

How does Transcat compare to Frequency Electronics?

Do institutionals and insiders hold more shares of FEIM or TRNS?

Which has more risk and volatility, FEIM or TRNS?

Is FEIM or TRNS more profitable?

Does the media prefer FEIM or TRNS?

Which has better valuation & earnings, FEIM or TRNS?

Do analysts rate FEIM or TRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRNS vs. The Competition

Transcat Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools